Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.
Patients Registration •It is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms. Procedure •six months once a month intravenous immunoglobulin (400mg/kg/4weeks)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
Infection rate
6 months after treatment compared to before treatment 6 months
Time frame: 6months
lung funtion
\- Lung function (FEV1) compared
Time frame: 6 months
steroid
\- Systemic steroid dose and the number of uses
Time frame: 6 months af
antibiotic
\- The frequency and duration of antibiotic
Time frame: 6months
asthma syptoms
\- The frequency of asthma exacerbations
Time frame: 6months
Questionnaire
\- Asthma Quality of Life (AQOL)
Time frame: 6months
Questionnair
\- Asthma control score (K-ACT)
Time frame: 6months
IgG subclass
\- Before and after treatment serum IgG subclass
Time frame: 6months
Cytokines
\- Cytokines serum levels before and after treatment
Time frame: 6months
adverse events
\- The frequency of adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6months